A detailed history of Private Advisor Group, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Private Advisor Group, LLC holds 30,270 shares of ESPR stock, worth $61,448. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,270
Previous 30,170 0.33%
Holding current value
$61,448
Previous $66,000 25.76%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

BUY
$1.61 - $2.73 $161 - $273
100 Added 0.33%
30,270 $49,000
Q2 2024

Aug 05, 2024

BUY
$1.84 - $3.24 $2,469 - $4,348
1,342 Added 4.66%
30,170 $66,000
Q4 2023

Feb 06, 2024

BUY
$0.73 - $3.08 $162 - $683
222 Added 0.78%
28,828 $86,000
Q2 2023

Aug 09, 2023

BUY
$1.2 - $1.76 $34,327 - $50,346
28,606 New
28,606 $39,000
Q3 2020

Nov 02, 2020

SELL
$31.18 - $52.71 $36,511 - $61,723
-1,171 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$30.04 - $51.31 $35,176 - $60,084
1,171 New
1,171 $60,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $135M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Private Advisor Group, LLC Portfolio

Follow Private Advisor Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Advisor Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Advisor Group, LLC with notifications on news.